On May 20, 2024, US District Court Judge Michael W. Fitzgerald rejected a popular over-the-counter eyedrop seller’s bid for a new trial and granted a pricing injunction impacting two large wholesale membership clubs following one of very few Robinson-Patman Act (RPA) plaintiff-side jury verdicts in recent years.
The case, L.A. International Corporation v. Prestige Brands Holdings, Inc., centered around popular eye drops called Clear Eyes® (Clear Eyes) sold by Medtech Products Inc. (Medtech) to wholesalers. The plaintiffs – a group of regional wholesalers (Plaintiffs) who purchased Clear Eyes for resale to retailers – sued Medtech and its parent company, Prestige Consumer Healthcare Inc. (together, Medtech or Defendants), in the US District Court for the Central District of California in August 2018.
